ShanghaiApril 22, 2026 /PRNewswire/ — Insilico Medicine (“Insilico” or the “Company”, HKEX stock code: 03696), a clinical-stage biotechnology company powered by generative AI, today announced the formation of the industry’s first Longevity Committee. This committee aims to provide scientific oversight and strategic guidance for AI-enabled aging research and drug discovery, empowering the development of therapeutics targeting the underlying biological mechanisms of aging. It seeks to drive a paradigm shift from reactive disease care towards proactive extension of healthspan and peak lifespan. The committee’s focus areas include: research on models of life, development of aging biomarkers, identification of dual-purpose targets relevant to both aging/longevity and disease, and clinical development to validate the impact of therapeutic candidates on key hallmarks of aging through biomarkers and foundational models.
Insilico Medicine Announces Formation of Industry’s First Longevity Committee to Accelerate AI-Driven Aging Research and Drug Discovery
Building a Bridge Between Big Pharma and Longevity Science
The inaugural committee brings together several influential scientists in the fields of aging and disease research, including:
- Dr. Andrew Adams, Vice President of Molecular Discovery at Eli Lilly and Company
- Dr. Michael Levitt, 2013 Nobel Laureate in Chemistry and member of Insilico Medicine’s Scientific Advisory Board;
- Dr. Denitsa Milanova, Founder and CEO of Medici Therapeutics and member of Insilico Medicine’s Board of Directors
- Dr. Alex Zhavoronkov, Co-CEO of Insilico Medicine and member of the Board of Directors
- Dr. Feng Ren, Co-CEO of Insilico Medicine and member of the Board of Directors
- Dr. Chuanxin Liang, Healthcare Partner at Value Partners Group and member of Insilico Medicine’s Board of Directors
Dr. Andrew Adams, Vice President of Molecular Discovery at Eli Lilly and Company, will serve as the Committee Chair. This key role is designed to bridge the critical gap between cutting-edge longevity science and large-scale pharmaceutical R&D.
A widely recognized leader in drug modality innovation, Dr. Adams has delivered impactful presentations at the 11th and 12th Aging Research and Drug Discovery (ARDD) conferences, garnering significant industry attention. His keynote address, “GLP-1: The World’s First Longevity Drug?”, clearly articulated the emerging value of metabolic regulation mechanisms in longevity research, aligning closely with Insilico’s vision of extending healthy, high-quality lifespan through dual-purpose therapeutics.
As Committee Chair, Dr. Adams will leverage his deep experience in early-stage drug discovery and large-scale R&D operations to provide expert insights for Insilico’s generative AI platform. He will help advance longevity-focused drug candidates towards commercialization, accelerating the development of longevity-related therapeutics with high clinical value and commercial potential for integration into mainstream healthcare systems.
A New Wave in Longevity Research
In recent years, longevity research has gained significant global momentum, though its origins trace back to the 1990s. Pioneers at that time began exploring direct interventions in aging, investigating various potential pathways including telomerase activation and stem cell biology.
Today, a new generation of longevity biotech companies is advancing the field with more pragmatic, clinically-aligned strategies. Rather than targeting “anti-aging” interventions directly, they focus on disease areas highly correlated with aging, such as obesity, muscle atrophy, metabolic disorders, fibrosis, anemia, and cancer. This strategy aims to first develop drug candidates for aging-related indications, then potentially expand their application to broader aging-related interventions.
Leveraging generative AI, Insilico can identify dual-effect targets at the critical intersection of chronic diseases and biological aging. This approach drives the development of innovative therapies that address immediate clinical needs while holding promise for modulating underlying aging mechanisms, advancing from disease intervention to healthspan extension and leading a new wave in longevity research.
Over a Decade of Dedication to Longevity Science
Dr. Michael Levitt, 2013 Nobel Laureate in Chemistry, stated, “Since Alex and I began collaborating over a decade ago, longevity science has made tremendous progress. What excites me most about this committee is its combination of rigorous biological insight with the large-scale computational power capable of delivering breakthroughs. Aging is not an isolated problem but a complex network of highly intertwined molecular and cellular processes. Only with sufficiently advanced AI tools to systematically analyze and intervene in this complexity do we have a real chance to extend lifespan and, consequently, healthspan. I am proud to be part of such a profoundly meaningful, scientifically grounded, and truly visionary endeavor.”
Longevity science has been integral to Insilico Medicine’s mission since its inception. As early as the 2015 NVIDIA GTC conference, Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, sparked widespread discussion in the tech community with the question, “Can NVIDIA Cure Aging?”. To date, Insilico scientists have published over 50 papers related to aging and longevity research, covering areas such as aging biomarkers, therapeutic targets with potential to intervene in both aging and disease, and corresponding therapeutic approaches.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery and drive innovation in life sciences, empowering humans to live longer, healthier lives. The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 30, 2025, under the stock code 03696.HK.
Utilizing its proprietary Pharma.AI platform and advanced automated biology laboratories, Insilico Medicine is delivering innovative drug solutions for disease areas with high unmet needs, including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Furthermore, Insilico continues to expand the application of Pharma.AI into diverse fields such as advanced materials, agriculture, nutritional products, and veterinary medicine. For more information, please visit www.insilico.com.